Shandong Buchang Pharmaceuticals (603858) Fundamentals 2026 — P/E 45.7x, Revenue Analysis | SniperIQ
Shandong Buchang Pharmaceuticals (603858) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥16.9B, trading at ¥16.00 on the SHH. This SniperIQ fundamentals page covers Shandong Buchang Pharmaceuticals's valuation (P/E 45.7x, P/B 1.6x), profitability (net margin 3.2%), revenue (¥11.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Buchang Pharmaceuticals's market cap?
Shandong Buchang Pharmaceuticals (603858) has a market capitalization of approximately ¥16.9B, trading at ¥16.00 on the SHH. Market cap moves with the live share price.
What is Shandong Buchang Pharmaceuticals's P/E ratio?
Shandong Buchang Pharmaceuticals's trailing twelve-month P/E ratio is 45.7x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shandong Buchang Pharmaceuticals?
Shandong Buchang Pharmaceuticals runs a net profit margin of 3.2%, a gross margin of 63.0%, and an operating margin of 9.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Buchang Pharmaceuticals generate?
Shandong Buchang Pharmaceuticals reported revenue of ¥11.8B for fiscal year 2025, with net income of ¥361M and earnings per share (EPS) of 0.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Buchang Pharmaceuticals pay a dividend?
Shandong Buchang Pharmaceuticals offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Buchang Pharmaceuticals financially healthy?
Shandong Buchang Pharmaceuticals carries a debt-to-equity ratio of 0.45x and a current ratio of 1.22x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Buchang Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Buchang Pharmaceuticals (603858) the key facts are: market cap ¥16.9B, P/E 45.7x, revenue ¥11.8B, 52-week range 14.01-20.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shandong Buchang Pharmaceuticals's full fundamentals live
Get Shandong Buchang Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.